Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Depreciation & Amortization (CF) (2023 - 2025)

Immunome's Depreciation & Amortization (CF) history spans 3 years, with the latest figure at $629000.0 for Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) rose 39.78% year-over-year to $629000.0; the TTM value through Dec 2025 reached $2.5 million, up 57.37%, while the annual FY2025 figure was $2.5 million, 57.37% up from the prior year.
  • Depreciation & Amortization (CF) reached $629000.0 in Q4 2025 per IMNM's latest filing, up from $589000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $637000.0 in Q2 2025 to a low of $94000.0 in Q1 2023.
  • Average Depreciation & Amortization (CF) over 3 years is $374166.7, with a median of $430500.0 recorded in 2024.
  • Peak YoY movement for Depreciation & Amortization (CF): skyrocketed 443.56% in 2024, then grew 16.03% in 2025.
  • A 3-year view of Depreciation & Amortization (CF) shows it stood at $151000.0 in 2023, then soared by 198.01% to $450000.0 in 2024, then soared by 39.78% to $629000.0 in 2025.
  • Per Business Quant, the three most recent readings for IMNM's Depreciation & Amortization (CF) are $629000.0 (Q4 2025), $589000.0 (Q3 2025), and $637000.0 (Q2 2025).